adl 5747
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT00979953)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Delta opioid receptorAGONIST
OPRD1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- adl5747
- adl5747
- adl5747
- adl 5747
- adl-5747
- n,n-diethyl-3-hydroxy-4-(spiro(chromene-2,4'-piperidine)-4-yl)benzamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01058642 | Phase 2 | Jan 1, 2010 | Cubist, Pfizer |
| NCT00979953 | Phase 2 | Oct 1, 2009 | Cubist, Pfizer |
Showing 2 of 2 trials
Page 1 / 1